Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Agios Pharmaceuticals (AGIO) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Agios Pharmaceuticals (AGIO) over the last 13 years, with Q3 2025 value amounting to -$103.4 million.

  • Agios Pharmaceuticals' Net Income towards Common Stockholders fell 11091.16% to -$103.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$403.0 million, marking a year-over-year decrease of 16005.72%. This contributed to the annual value of $673.7 million for FY2024, which is N/A changed from last year.
  • Latest data reveals that Agios Pharmaceuticals reported Net Income towards Common Stockholders of -$103.4 million as of Q3 2025, which was down 11091.16% from -$112.5 million recorded in Q2 2025.
  • Agios Pharmaceuticals' Net Income towards Common Stockholders' 5-year high stood at $2.0 billion during Q1 2021, with a 5-year trough of -$112.5 million in Q2 2025.
  • For the 4-year period, Agios Pharmaceuticals' Net Income towards Common Stockholders averaged around $131.3 million, with its median value being -$85.4 million (2023).
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first skyrocketed by 438287.33% in 2021, then plummeted by 11091.16% in 2025.
  • Over the past 4 years, Agios Pharmaceuticals' Net Income towards Common Stockholders (Quarter) stood at $4.0 million in 2021, then plummeted by 2524.56% to -$95.9 million in 2023, then decreased by 0.61% to -$96.5 million in 2024, then decreased by 7.16% to -$103.4 million in 2025.
  • Its Net Income towards Common Stockholders was -$103.4 million in Q3 2025, compared to -$112.5 million in Q2 2025 and -$90.5 million in Q1 2025.